Global Hepatitis C Drugs Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Hepatitis is inflammation of the liver characterized by yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay colored stools etc.

Report Overview

Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Hepatitis C Drugs estimated at US$ 6465.7 million in the year 2022, is projected to reach a revised size of US$ 7856.3 million by 2028, growing at a CAGR of 3.3% during the forecast period 2022-2028.

Hepatitis is caused by a variety of factors both microbial and non-microbial. However hepatitis C is caused by hepatitis C virus and affects between 130–150 million people globally every year of which approximately 700 000 people die from hepatitis C-related liver diseases. What is of greater concern is the fact that 15 to 20% of chronically infected patients develop liver cirrhosis or liver cancer.

Report Scope

This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Hepatitis C Drugs companies, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.

This report also includes a discussion of the major players across each regional Hepatitis C Drugs market. Further, it explains the major drivers and regional dynamics of the global Hepatitis C Drugs market and current trends within the industry.

Key Companies Covered

In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:

Gilead sciences

Abbvi

Johnson & Johnson

Merck

Glaxosmithkline

Novartis

Bristol-Myers Squibb

Roche

Market Segments

This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.

Anti-Viral

Immuno-modulators

Others

Hospitals

Clinics

Key Regions & Countries

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Hepatitis C Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Report Includes:

This report presents an overview of global market for Hepatitis C Drugs market size. Analyses of the global market trends, with historic market revenue data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.

This report researches the key producers of Hepatitis C Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Hepatitis C Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hepatitis C Drugs revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Hepatitis C Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Hepatitis C Drugs revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Gilead sciences, Abbvi, Johnson & Johnson, Merck, Glaxosmithkline, Novartis, Bristol-Myers Squibb and Roche, etc.

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Hepatitis C Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028

1.2.2 Anti-Viral

1.2.3 Immuno-modulators

1.2.4 Others

1.3 Market by Application

1.3.1 Global Hepatitis C Drugs Market Growth Rate by Application: 2017 VS 2021 VS 2028

1.3.2 Hospitals

1.3.3 Clinics

1.4 Study Objectives

1.5 Years Considered

2.1 Global Hepatitis C Drugs Market Size (2017-2028)

2.2 Hepatitis C Drugs Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028

2.3 Global Hepatitis C Drugs Market Size by Region (2017-2022)

2.4 Global Hepatitis C Drugs Market Size Forecast by Region (2023-2028)

2.5 Global Top Hepatitis C Drugs Countries Ranking by Market Size

3.1 Global Hepatitis C Drugs Revenue by Players

3.1.1 Global Hepatitis C Drugs Revenue by Players (2017-2022)

3.1.2 Global Hepatitis C Drugs Market Share by Players (2017-2022)

3.2 Global Hepatitis C Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Company Covered: Ranking by Hepatitis C Drugs Revenue

3.4 Global Hepatitis C Drugs Market Concentration Ratio

3.4.1 Global Hepatitis C Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Hepatitis C Drugs Revenue in 2021

3.5 Global Hepatitis C Drugs Key Players Head office and Area Served

3.6 Key Players Hepatitis C Drugs Product Solution and Service

3.7 Date of Enter into Hepatitis C Drugs Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Hepatitis C Drugs Historic Revenue by Type (2017-2022)

4.2 Global Hepatitis C Drugs Forecasted Revenue by Type (2023-2028)

5.1 Global Hepatitis C Drugs Historic Market Size by Application (2017-2022)

5.2 Global Hepatitis C Drugs Forecasted Market Size by Application (2023-2028)

6.1 North America Hepatitis C Drugs Revenue by Company (2020-2022)

6.2 North America Hepatitis C Drugs Revenue by Type (2017-2028)

6.3 North America Hepatitis C Drugs Revenue by Application (2017-2028)

6.4 North America Hepatitis C Drugs Revenue by Country (2017-2028)

6.4.1 U.S.

6.4.2 Canada

7.1 Europe Hepatitis C Drugs Revenue by Company (2020-2022)

7.2 Europe Hepatitis C Drugs Revenue by Type (2017-2028)

7.3 Europe Hepatitis C Drugs Revenue by Application (2017-2028)

7.4 Europe Hepatitis C Drugs Revenue by Country (2017-2028)

7.4.1 Germany

7.4.2 France

7.4.3 U.K.

7.4.4 Italy

7.4.5 Russia

8.1 Asia Pacific Hepatitis C Drugs Revenue by Company (2020-2022)

8.2 Asia Pacific Hepatitis C Drugs Revenue by Type (2017-2028)

8.3 Asia Pacific Hepatitis C Drugs Revenue by Application (2017-2028)

8.4 Asia Pacific Hepatitis C Drugs Revenue by Region (2017-2028)

8.4.1 China

8.4.2 Japan

8.4.3 South Korea

8.4.4 India

8.4.5 Australia

8.4.6 Taiwan

8.4.7 Indonesia

8.4.8 Thailand

8.4.9 Malaysia

8.4.10 Philippines

8.4.11 Vietnam

9.1 Latin America Hepatitis C Drugs Revenue by Company (2020-2022)

9.2 Latin America Hepatitis C Drugs Revenue by Type (2017-2028)

9.3 Latin America Hepatitis C Drugs Revenue by Application (2017-2028)

9.4 Latin America Hepatitis C Drugs Revenue by Country (2017-2028)

9.4.1 Mexico

9.4.2 Brazil

9.4.3 Argentina

10.1 Middle East and Africa Hepatitis C Drugs Revenue by Company (2020-2022)

10.2 Middle East and Africa Hepatitis C Drugs Revenue by Type (2017-2028)

10.3 Middle East and Africa Hepatitis C Drugs Revenue by Application (2017-2028)

10.4 Middle East and Africa Hepatitis C Drugs Revenue by Country (2017-2028)

10.4.1 Turkey

10.4.2 Saudi Arabia

10.4.3 U.A.E

11.1 Gilead sciences

11.1.1 Gilead sciences Company Details

11.1.2 Gilead sciences Business Overview

11.1.3 Gilead sciences Hepatitis C Drugs Products and Services

11.1.4 Gilead sciences Hepatitis C Drugs Revenue in Hepatitis C Drugs Business (2017-2022)

11.1.5 Gilead sciences Hepatitis C Drugs SWOT Analysis

11.1.6 Gilead sciences Recent Developments

11.2 Abbvi

11.2.1 Abbvi Company Details

11.2.2 Abbvi Business Overview

11.2.3 Abbvi Hepatitis C Drugs Products and Services

11.2.4 Abbvi Hepatitis C Drugs Revenue in Hepatitis C Drugs Business (2017-2022)

11.2.5 Abbvi Hepatitis C Drugs SWOT Analysis

11.2.6 Abbvi Recent Developments

11.3 Johnson & Johnson

11.3.1 Johnson & Johnson Company Details

11.3.2 Johnson & Johnson Business Overview

11.3.3 Johnson & Johnson Hepatitis C Drugs Products and Services

11.3.4 Johnson & Johnson Hepatitis C Drugs Revenue in Hepatitis C Drugs Business (2017-2022)

11.3.5 Johnson & Johnson Hepatitis C Drugs SWOT Analysis

11.3.6 Johnson & Johnson Recent Developments

11.4 Merck

11.4.1 Merck Company Details

11.4.2 Merck Business Overview

11.4.3 Merck Hepatitis C Drugs Products and Services

11.4.4 Merck Hepatitis C Drugs Revenue in Hepatitis C Drugs Business (2017-2022)

11.4.5 Merck Hepatitis C Drugs SWOT Analysis

11.4.6 Merck Recent Developments

11.5 Glaxosmithkline

11.5.1 Glaxosmithkline Company Details

11.5.2 Glaxosmithkline Business Overview

11.5.3 Glaxosmithkline Hepatitis C Drugs Products and Services

11.5.4 Glaxosmithkline Hepatitis C Drugs Revenue in Hepatitis C Drugs Business (2017-2022)

11.5.5 Glaxosmithkline Hepatitis C Drugs SWOT Analysis

11.5.6 Glaxosmithkline Recent Developments

11.6 Novartis

11.6.1 Novartis Company Details

11.6.2 Novartis Business Overview

11.6.3 Novartis Hepatitis C Drugs Products and Services

11.6.4 Novartis Hepatitis C Drugs Revenue in Hepatitis C Drugs Business (2017-2022)

11.6.5 Novartis Hepatitis C Drugs SWOT Analysis

11.6.6 Novartis Recent Developments

11.7 Bristol-Myers Squibb

11.7.1 Bristol-Myers Squibb Company Details

11.7.2 Bristol-Myers Squibb Business Overview

11.7.3 Bristol-Myers Squibb Hepatitis C Drugs Products and Services

11.7.4 Bristol-Myers Squibb Hepatitis C Drugs Revenue in Hepatitis C Drugs Business (2017-2022)

11.7.5 Bristol-Myers Squibb Hepatitis C Drugs SWOT Analysis

11.7.6 Bristol-Myers Squibb Recent Developments

11.8 Roche

11.8.1 Roche Company Details

11.8.2 Roche Business Overview

11.8.3 Roche Hepatitis C Drugs Products and Services

11.8.4 Roche Hepatitis C Drugs Revenue in Hepatitis C Drugs Business (2017-2022)

11.8.5 Roche Hepatitis C Drugs SWOT Analysis

11.8.6 Roche Recent Developments

12.1 Hepatitis C Drugs Market Trends

12.2 Hepatitis C Drugs Market Drivers

12.3 Hepatitis C Drugs Market Challenges

12.4 Hepatitis C Drugs Market Restraints

14.1 Research Methodology

14.1.1 Methodology/Research Approach

14.1.2 Data Source

14.2 Author Details

List of Tables

    Table 1. Global Hepatitis C Drugs Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028

    Table 2. Key Players of Anti-Viral

    Table 3. Key Players of Immuno-modulators

    Table 4. Key Players of Others

    Table 5. Global Hepatitis C Drugs Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028

    Table 6. Global Hepatitis C Drugs Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028

    Table 7. Global Hepatitis C Drugs Revenue by Region (2017-2022) & (US$ Million)

    Table 8. Global Hepatitis C Drugs Revenue Market Share by Region (2017-2022)

    Table 9. Global Hepatitis C Drugs Revenue by Players (2017-2022) & (US$ Million)

    Table 10. Global Hepatitis C Drugs Market Share by Players (2017-2022)

    Table 11. Global Top Hepatitis C Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatitis C Drugs as of 2021)

    Table 12. Ranking of Global Top Hepatitis C Drugs Companies by Revenue (US$ Million) in 2021

    Table 13. Global 5 Largest Players Market Share by Hepatitis C Drugs Revenue (CR5 and HHI) & (2017-2022)

    Table 14. Key Players Headquarters and Area Served

    Table 15. Key Players Hepatitis C Drugs Product Solution and Service

    Table 16. Date of Key Manufacturers Enter into Hepatitis C Drugs Market

    Table 17. Mergers & Acquisitions, Expansion Plans

    Table 18. Global Hepatitis C Drugs Market Size by Type (2017-2022) & (US$ Million)

    Table 19. Global Hepatitis C Drugs Revenue Market Share by Type (2017-2022)

    Table 20. Global Hepatitis C Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)

    Table 21. Global Hepatitis C Drugs Revenue Market Share by Type (2023-2028)

    Table 22. Global Hepatitis C Drugs Market Size by Application (2017-2022) & (US$ Million)

    Table 23. Global Hepatitis C Drugs Revenue Market Share by Application (2017-2022)

    Table 24. Global Hepatitis C Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)

    Table 25. Global Hepatitis C Drugs Revenue Market Share by Application (2023-2028)

    Table 26. North America Hepatitis C Drugs Revenue by Company (2020-2022) & (US$ Million)

    Table 27. North America Hepatitis C Drugs Revenue by Type (2017-2022) & (US$ Million)

    Table 28. North America Hepatitis C Drugs Revenue by Type (2023-2028) & (US$ Million)

    Table 29. North America Hepatitis C Drugs Revenue by Application (2017-2022) & (US$ Million)

    Table 30. North America Hepatitis C Drugs Revenue by Application (2023-2028) & (US$ Million)

    Table 31. North America Hepatitis C Drugs Revenue by Country (2017-2022) & (US$ Million)

    Table 32. North America Hepatitis C Drugs Revenue by Country (2023-2028) & (US$ Million)

    Table 33. Europe Hepatitis C Drugs Revenue by Company (2020-2022) & (US$ Million)

    Table 34. Europe Hepatitis C Drugs Revenue by Type (2017-2022) & (US$ Million)

    Table 35. Europe Hepatitis C Drugs Revenue by Type (2023-2028) & (US$ Million)

    Table 36. Europe Hepatitis C Drugs Revenue by Application (2017-2022) & (US$ Million)

    Table 37. Europe Hepatitis C Drugs Revenue by Application (2023-2028) & (US$ Million)

    Table 38. Europe Hepatitis C Drugs Revenue by Country (2017-2022) & (US$ Million)

    Table 39. Europe Hepatitis C Drugs Revenue by Country (2023-2028) & (US$ Million)

    Table 40. Asia Pacific Hepatitis C Drugs Revenue by Company (2020-2022) & (US$ Million)

    Table 41. Asia Pacific Hepatitis C Drugs Revenue by Type (2017-2022) & (US$ Million)

    Table 42. Asia Pacific Hepatitis C Drugs Revenue by Type (2023-2028) & (US$ Million)

    Table 43. Asia Pacific Hepatitis C Drugs Revenue by Application (2017-2022) & (US$ Million)

    Table 44. Asia Pacific Hepatitis C Drugs Revenue by Application (2023-2028) & (US$ Million)

    Table 45. Asia Pacific Hepatitis C Drugs Revenue by Region (2017-2022) & (US$ Million)

    Table 46. Asia Pacific Hepatitis C Drugs Revenue by Region (2023-2028) & (US$ Million)

    Table 47. Latin America Hepatitis C Drugs Revenue by Company (2020-2022) & (US$ Million)

    Table 48. Latin America Hepatitis C Drugs Revenue by Type (2017-2022) & (US$ Million)

    Table 49. Latin America Hepatitis C Drugs Revenue by Type (2023-2028) & (US$ Million)

    Table 50. Latin America Hepatitis C Drugs Revenue by Application (2017-2022) & (US$ Million)

    Table 51. Latin America Hepatitis C Drugs Revenue by Application (2023-2028) & (US$ Million)

    Table 52. Latin America Hepatitis C Drugs Revenue by Country (2017-2022) & (US$ Million)

    Table 53. Latin America Hepatitis C Drugs Revenue by Country (2023-2028) & (US$ Million)

    Table 54. Middle East and Africa Hepatitis C Drugs Revenue by Company (2020-2022) & (US$ Million)

    Table 55. Middle East and Africa Hepatitis C Drugs Revenue by Type (2017-2022) & (US$ Million)

    Table 56. Middle East and Africa Hepatitis C Drugs Revenue by Type (2023-2028) & (US$ Million)

    Table 57. Middle East and Africa Hepatitis C Drugs Revenue by Application (2017-2022) & (US$ Million)

    Table 58. Middle East and Africa Hepatitis C Drugs Revenue by Application (2023-2028) & (US$ Million)

    Table 59. Middle East and Africa Hepatitis C Drugs Revenue by Country (2017-2022) & (US$ Million)

    Table 60. Middle East and Africa Hepatitis C Drugs Revenue by Country (2023-2028) & (US$ Million)

    Table 61. Gilead sciences Company Details

    Table 62. Gilead sciences Business Overview

    Table 63. Gilead sciences Hepatitis C Drugs Product and Services

    Table 64. Gilead sciences Hepatitis C Drugs Revenue in Hepatitis C Drugs Business (2017-2022) & (US$ Million)

    Table 65. Gilead sciences Hepatitis C Drugs SWOT Analysis

    Table 66. Gilead sciences Recent Developments

    Table 67. Abbvi Company Details

    Table 68. Abbvi Business Overview

    Table 69. Abbvi Hepatitis C Drugs Product and Services

    Table 70. Abbvi Hepatitis C Drugs Revenue in Hepatitis C Drugs Business (2017-2022) & (US$ Million)

    Table 71. Abbvi Hepatitis C Drugs SWOT Analysis

    Table 72. Abbvi Recent Developments

    Table 73. Johnson & Johnson Company Details

    Table 74. Johnson & Johnson Business Overview

    Table 75. Johnson & Johnson Hepatitis C Drugs Product and Services

    Table 76. Johnson & Johnson Hepatitis C Drugs Revenue in Hepatitis C Drugs Business (2017-2022) & (US$ Million)

    Table 77. Johnson & Johnson Hepatitis C Drugs SWOT Analysis

    Table 78. Johnson & Johnson Recent Developments

    Table 79. Merck Company Details

    Table 80. Merck Business Overview

    Table 81. Merck Hepatitis C Drugs Product and Services

    Table 82. Merck Hepatitis C Drugs Revenue in Hepatitis C Drugs Business (2017-2022) & (US$ Million)

    Table 83. Merck Hepatitis C Drugs SWOT Analysis

    Table 84. Merck Recent Developments

    Table 85. Glaxosmithkline Company Details

    Table 86. Glaxosmithkline Business Overview

    Table 87. Glaxosmithkline Hepatitis C Drugs Product and Services

    Table 88. Glaxosmithkline Hepatitis C Drugs Revenue in Hepatitis C Drugs Business (2017-2022) & (US$ Million)

    Table 89. Glaxosmithkline Hepatitis C Drugs SWOT Analysis

    Table 90. Glaxosmithkline Recent Developments

    Table 91. Novartis Company Details

    Table 92. Novartis Business Overview

    Table 93. Novartis Hepatitis C Drugs Product and Services

    Table 94. Novartis Hepatitis C Drugs Revenue in Hepatitis C Drugs Business (2017-2022) & (US$ Million)

    Table 95. Novartis Hepatitis C Drugs SWOT Analysis

    Table 96. Novartis Recent Developments

    Table 97. Bristol-Myers Squibb Company Details

    Table 98. Bristol-Myers Squibb Business Overview

    Table 99. Bristol-Myers Squibb Hepatitis C Drugs Product and Services

    Table 100. Bristol-Myers Squibb Hepatitis C Drugs Revenue in Hepatitis C Drugs Business (2017-2022) & (US$ Million)

    Table 101. Bristol-Myers Squibb Hepatitis C Drugs SWOT Analysis

    Table 102. Bristol-Myers Squibb Recent Developments

    Table 103. Roche Company Details

    Table 104. Roche Business Overview

    Table 105. Roche Hepatitis C Drugs Product and Services

    Table 106. Roche Hepatitis C Drugs Revenue in Hepatitis C Drugs Business (2017-2022) & (US$ Million)

    Table 107. Roche Hepatitis C Drugs SWOT Analysis

    Table 108. Roche Recent Developments

    Table 109. Hepatitis C Drugs Market Trends

    Table 110. Hepatitis C Drugs Market Drivers

    Table 111. Hepatitis C Drugs Market Challenges

    Table 112. Hepatitis C Drugs Market Restraints

    Table 113. Research Programs/Design for This Report

    Table 114. Key Data Information from Secondary Sources

    Table 115. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Hepatitis C Drugs Sales Market Share by Type: 2021 VS 2028

    Figure 2. Anti-Viral Features

    Figure 3. Immuno-modulators Features

    Figure 4. Others Features

    Figure 5. Global Hepatitis C Drugs Sales Market Share by Application: 2021 VS 2028

    Figure 6. Hospitals Case Studies

    Figure 7. Clinics Case Studies

    Figure 8. Hepatitis C Drugs Report Years Considered

    Figure 9. Global Hepatitis C Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028

    Figure 10. Global Hepatitis C Drugs Market Size 2017-2028 (US$ Million)

    Figure 11. Global Hepatitis C Drugs Market Size Market Share by Region: 2021 VS 2028

    Figure 12. Global Hepatitis C Drugs Revenue Market Share by Region in 2017 VS 2022

    Figure 13. Global Top 10 Hepatitis C Drugs Countries Ranking by Market Size (US$ Million) in 2021

    Figure 14. Global Hepatitis C Drugs Market Share by Players in 2021

    Figure 15. Global Top Hepatitis C Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatitis C Drugs as of 2021)

    Figure 16. The Top 10 and 5 Players Market Share by Hepatitis C Drugs Revenue in 2021

    Figure 17. North America Hepatitis C Drugs Revenue Market Share by Company in 2021

    Figure 18. North America Hepatitis C Drugs Revenue Market Share by Type (2017-2028)

    Figure 19. North America Hepatitis C Drugs Revenue Market Share by Application (2017-2028)

    Figure 20. North America Hepatitis C Drugs Revenue Share by Country (2017-2028)

    Figure 21. U.S. Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 22. Canada Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 23. Europe Hepatitis C Drugs Revenue Market Share by Company in 2021

    Figure 24. Europe Hepatitis C Drugs Revenue Market Share by Type (2017-2028)

    Figure 25. Europe Hepatitis C Drugs Revenue Market Share by Application (2017-2028)

    Figure 26. Europe Hepatitis C Drugs Revenue Share by Country (2017-2028)

    Figure 27. Germany Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 28. France Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 29. U.K. Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 30. Italy Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 31. Russia Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 32. Asia Pacific Hepatitis C Drugs Revenue Market Share by Company in 2021

    Figure 33. Asia Pacific Hepatitis C Drugs Revenue Market Share by Type (2017-2028)

    Figure 34. Asia Pacific Hepatitis C Drugs Revenue Market Share by Application (2017-2028)

    Figure 35. Asia Pacific Hepatitis C Drugs Revenue Share by Region (2017-2028)

    Figure 36. China Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 37. Japan Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 38. South Korea Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 39. India Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 40. Australia Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 41. Taiwan Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 42. Indonesia Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 43. Thailand Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 44. Malaysia Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 45. Philippines Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 46. Vietnam Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 47. Latin America Hepatitis C Drugs Revenue Market Share by Company in 2021

    Figure 48. Latin America Hepatitis C Drugs Revenue Market Share by Type (2017-2028)

    Figure 49. Latin America Hepatitis C Drugs Revenue Market Share by Application (2017-2028)

    Figure 50. Latin America Hepatitis C Drugs Revenue Share by Country (2017-2028)

    Figure 51. Mexico Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 52. Brazil Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 53. Argentina Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 54. Middle East and Africa Hepatitis C Drugs Revenue Market Share by Company in 2021

    Figure 55. Middle East and Africa Hepatitis C Drugs Revenue Market Share by Type (2017-2028)

    Figure 56. Middle East and Africa Hepatitis C Drugs Revenue Market Share by Application (2017-2028)

    Figure 57. Middle East and Africa Hepatitis C Drugs Revenue Share by Country (2017-2028)

    Figure 58. Turkey Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 59. Saudi Arabia Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 60. U.A.E Hepatitis C Drugs Revenue (2017-2028) & (US$ Million)

    Figure 61. Gilead sciences Revenue Growth Rate in Hepatitis C Drugs Business (2017-2022)

    Figure 62. Abbvi Revenue Growth Rate in Hepatitis C Drugs Business (2017-2022)

    Figure 63. Johnson & Johnson Revenue Growth Rate in Hepatitis C Drugs Business (2017-2022)

    Figure 64. Merck Revenue Growth Rate in Hepatitis C Drugs Business (2017-2022)

    Figure 65. Glaxosmithkline Revenue Growth Rate in Hepatitis C Drugs Business (2017-2022)

    Figure 66. Novartis Revenue Growth Rate in Hepatitis C Drugs Business (2017-2022)

    Figure 67. Bristol-Myers Squibb Revenue Growth Rate in Hepatitis C Drugs Business (2017-2022)

    Figure 68. Roche Revenue Growth Rate in Hepatitis C Drugs Business (2017-2022)

    Figure 69. Bottom-up and Top-down Approaches for This Report

    Figure 70. Data Triangulation

    Figure 71. Key Executives Interviewed